SciClone Pharmaceuticals (Holdings) Limited announced that the first subject has been dosed in the Phase III clinical trial of Vaborem® (Meropenem and Vaborbactam for injection) in China, a new antibacterial drug. This study is a Phase III, randomized, double-blind, double-dummy, active-controlled, multi-center clinical trial to be conducted in China to evaluate the efficacy and safety of Vaborem®? for patients with complicated urinary tract infections (" cUTI") including pyelonephritis.

The results of this study and a concurrent study in healthy volunteers in China to evaluate the pharmacokinetic profile of Vaborem®, are meant to bridge the foreign clinical trial data and eventually support the New Drug Application ("NDA") of Vaborem® in China. Vaborem®? is a fixed-dose combination of a carbapenem and a novel boronic acid b-lactamase inhibitor of class A and Class C serine b-lactamase.

Vaborbactam can inhibit various class A and class C b-lactamases, so it protects meropenem from degradation by serine carbapenemases, restoring meropenem's activity against carbapenem-resistant strains. Vaborem® has been specifically developed to inhibit carbapenem-resistant enterobacterales ("CRE") including the commonly found Klebsiella pneumoniae carbapenemase ("KPC")- producing bacteria. Currently Vaborem®?

has be granted marketing authorizations in the United States of America and the European Union, among other countries and regions, for adults with cUTI including pyelonephritis". In select territories, it has also been approved for the treatment of complicated intra-abdominal infections ("CIAI"), hospital- acquired bacterial pneumonia ("HABP") and ventilator-associated bacterial pneumonia ("VABP"). Pursuant to the License and Collaboration Agreement entered into between SciClone Pharmaceuticals and A. Menarini Asia-Pacific Holdings Pte.

Ltd., part of The Menarini Group ("Menarini"), in August 2022, the Company has the exclusive right to develop and commercial commercialize Vaborem® in China, under Menarini's head license agreement with Melinta Therapeutics Inc. In March 2023, the National Medical Products Administration (the "NMPA") in China officially approved the Company's Investigational New Drug (the "IND") application for Vaborem®. There is a continuous demand in China for novel anti-infectives that can effectively treat multidrug-resistant infections, as unmet medical needs persist. The Company looks forward to bringing Vaborem®, a novel antibiotic, to China through collaboration with Menarini.

Thanks to the collaborative efforts of the investigators, partners and the Company, the first subject has been dosed in Vaborem® Phase III clinical trial in China. The Company will accelerate the clinical development of Vaborem® and hope to provide more effective and safer treatment options as soon as possible for patients in China suffering from life threatening, multidrug-resistant infections.